5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 2 (40%) |
| No statute on record | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROZOF, TIMOTHY R | 1 | 72.6% | +24.0% |
| SAEED, KAMAL A | 1 | 84.1% | +9.3% |
| TRAN, SUSAN T | 1 | 62.8% | +36.0% |
| RAO, PADMAJA S | 1 | 69.5% | +35.9% |
| SEITZ, ANTHONY JOSEPH | 1 | 68.8% | +28.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18210215 | BLEND CONTAINING CARBAMATE COMPOUND FOR PREVENTION, MITIGATION, OR TREATMENT OF SCHIZOPHRENIA | SAEED, KAMAL A | 28d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17770704 | USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUND FOR PREVENTION, ALLEVIATION, OR TREATMENT OF DEVELOPMENTAL DISABILITY | SEITZ, ANTHONY JOSEPH | 99d overdue |
| 18019856 | SOLID ORAL COMPOSITION COMPRISING CARBAMATE COMPOUND, AND PREPARATION METHOD THEREFOR | TRAN, SUSAN T | 46d overdue |
| 18565188 | METHODS FOR TREATING AUTISM SPECTRUM DISORDERS (ASD) | ROZOF, TIMOTHY R | 23d overdue |
| 17770686 | USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUNDS FOR PREVENTION, ALLEVIATION, OR TREATMENT OF COGNITIVE DISORDERS, OR FOR IMPROVING COGNITIVE FUNCTION | RAO, PADMAJA S | 8d overdue |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1626 | 1 |
| 1615 | 1 |
| 1627 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18565188 | METHODS FOR TREATING AUTISM SPECTRUM DISORDERS (ASD) | ROZOF, TIMOTHY R | 1625 | §112 | Non-Final OA | 23d overdue | Pending | Nov 29, 2023 |
| 18210215 | BLEND CONTAINING CARBAMATE COMPOUND FOR PREVENTION, MITIGATION, OR TREATMENT OF SCHIZOPHRENIA | SAEED, KAMAL A | 1626 | §112 | Final Rejection | 28d | Pending | Jun 15, 2023 |
| 18019856 | SOLID ORAL COMPOSITION COMPRISING CARBAMATE COMPOUND, AND PREPARATION METHOD THEREFOR | TRAN, SUSAN T | 1615 | §103 | Final Rejection | 46d overdue | Pending | Feb 06, 2023 |
| 17770686 | USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUNDS FOR PREVENTION, ALLEVIATION, OR TREATMENT OF COGNITIVE DISORDERS, OR FOR IMPROVING COGNITIVE FUNCTION | RAO, PADMAJA S | 1627 | Other | Non-Final OA | 8d overdue | Pending | Apr 21, 2022 |
| 17770704 | USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUND FOR PREVENTION, ALLEVIATION, OR TREATMENT OF DEVELOPMENTAL DISABILITY | SEITZ, ANTHONY JOSEPH | 1629 | Other | Final Rejection | 99d overdue | Pending | Apr 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial